Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2009 March;34(1) > Minerva Endocrinologica 2009 March;34(1):57-69

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

REVIEWS  


Minerva Endocrinologica 2009 March;34(1):57-69

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases

De Klerk J. M. H., Oyen W. J. G.

Department of Nuclear Medicine Meander Medical Center, Amersfoort The Netherlands


PDF  


Radioiodine plays an important role in the treatment of thyroid cancer. It is used for thyroid remnant ablation as well as for treatment of metastatic disease. Despite the fact that it is used all over the world for these indications, the exact administered dose is still a subject for discussion. Two methods are widely available: the so-called fixed empiric method and the dosimetric one. This review will highlight the aspects of radioiodine in treatment of thyroid cancer and discuss the advantages and disadvantages of the several methods for the calculation of the administered dose.

top of page

Publication History

Cite this article as

Corresponding author e-mail